



Merlin

A GENE EXPRESSION-BASED TEST

BIBLIOGRAPHY

Scan the QR Code to access the publication



Model combining tumor molecular and clinicopathologic risk factors predicts sentinel lymph node metastasis in primary cutaneous melanoma.

Bellomo et al. 2020. JCO Precision Oncology.



Primary cutaneous melanoma risk stratification using a clinicopathologic and gene expression model: a pilot study.

Arias-Mejias et al. 2020. International Journal of Dermatology.



Deselecting melanoma patients for sentinel lymph node biopsy during COVID-19: clinical utility of tumor molecular profiling.

Meves & Eggermont 2020. Mayo Clin Proc Inn Qual Out.



Validation of a clinicopathological and gene expression profile model for sentinel lymph node metastasis in primary cutaneous melanoma.

Mulder et al. 2020. British Journal of Dermatology.



Validation of CP-GEP (Merlin Assay) for predicting sentinel lymph node metastasis in primary cutaneous melanoma patients: a U.S. cohort study.

Yousaf et al. 2021. International Journal of Dermatology.



A molecular model to identify patients who can safely forgo sentinel lymph node biopsy in primary cutaneous melanoma.

Bellomo et al. 2019. CIM Conference.



Stromal gene expression predicts sentinel lymph node metastasis of primary cutaneous melanoma.

Sominidi-Damodaran et al. 2019. EADO Conference.



Validation of a ClinicoPathological and Gene Expression Profile (CP-GEP) model for sentinel lymph node metastasis in primary cutaneous melanoma.

Mulder et al. 2019. ESMO Conference.



Validation of a Model Combining Clinicopathologic Risk Factors and a Gene Expression Profile to Identify Primary Melanoma Patients Who Can Safely Forgo Sentinel Lymph Node Biopsy.

Yousaf et al. 2020. ESMO Conference.



A combined clinicopathologic and gene expression model (CP-GEP) identifies primary cutaneous melanoma patients who can safely forgo sentinel lymph node biopsy.

Meves et al. 2020. AAD Conference.



The use of a clinicopathologic and gene expression model (Merlin Assay) to risk stratify cutaneous melanoma patients in clinical practice: A pilot study.

Bridges et al. 2020. ASDP Conference.



Independent validation study of CP-GEP model (Merlin Assay) to identify patients who can safely forgo sentinel lymph node biopsy.

Johansson et al. 2021. EADO Conference.



Using the clinicopathologic and gene expression (CP-GEP) model to predict sentinel node status in patients with primary melanoma: a prospective cohort study during the COVID-19 pandemic.

Mulder et al. 2021. EADO Conference.

